Browse the evidence

Fixed-ratio combinations of GLP-1 receptor agonists and basal insulin provide superior glycemic control and weight loss compared to insulin alone, without increasing hypoglycemia risk.

If you need insulin for diabetes, adding a GLP-1 drug might help you control your blood sugar better without gaining weight. It's a single injection that combines both medications.

Real-world users of semaglutide (Wegovy) for weight management rarely follow recommended dose titration protocols, with the majority stopping at or below 1.0 mg rather than reaching the target 2.4 mg dose evaluated in clinical trials.

If you are using Wegovy, know that most people do not reach the maximum 2.4 mg dose. Many stop at 1.0 mg due to side effects or cost. This does not mean the drug isn't working for you, but it may mean your weight loss potential is lower than what is seen in clinical trials. Discuss your dose with your provider to see if escalation is appropriate for your tolerance and financial situation.

In adults with prediabetes, women experience less sustained weight loss and greater loss of fat-free mass and bone mineral content compared to men during long-term lifestyle interventions, despite showing greater improvements in some cardiometabolic markers like fasting glucose and HDL.

Women in this study lost less weight and more muscle/bone than men following the same lifestyle program. To mitigate this, women should prioritize resistance training and protein intake to protect lean mass, and focus on metabolic improvements (like blood sugar and cholesterol) rather than just scale weight, as these may improve even if weight loss is modest.

Low-volume high-intensity interval training (LV-HIT) significantly reduces circulating miRNA-27b expression in women with polycystic ovary syndrome (PCOS), whereas high-volume HIT (HV-HIT) does not, despite both improving cardiorespiratory fitness.

For women with PCOS, low-volume high-intensity interval training (10 one-minute maximal efforts with rest) is effective at reducing circulating miRNA-27b levels, a marker linked to metabolism and inflammation. Interestingly, a higher-volume protocol (4x4 minutes) improved fitness but did not change this specific marker, suggesting that training volume and structure matter for molecular adaptations even when fitness gains are similar.

Women tend to lose more weight than men when treated with GLP-1 receptor agonists (semaglutide, liraglutide) for obesity, despite men often losing more weight with lifestyle interventions alone.

If you are a woman being treated with GLP-1 medications like Wegovy or Saxenda, you are statistically likely to lose more weight than a man on the same drug. This is due to how your body processes the medication. Do not compare your progress to male baselines or lifestyle-only results; your pharmacological response is typically superior.

Tirzepatide 15mg is associated with a higher risk of hypoglycemia compared to GLP-1 receptor agonists, although it has a lower risk of hypoglycemia compared to basal insulins.

If you are on the 15mg dose of Tirzepatide, especially if you also take insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) is higher than if you were on a standard GLP-1 drug like semaglutide. Monitor your blood sugar closely and discuss dose adjustments with your doctor if you experience symptoms of low blood sugar.

Naltrexone/bupropion reduces food cravings and reward-driven eating by antagonizing opioid receptors, thereby decreasing the subjective delightfulness of energy-dense foods.

If you struggle with intense cravings for sugary or fatty foods, standard dieting may fail because your brain's reward system is driving your intake. Naltrexone/bupropion targets this by blocking opioid receptors, reducing the 'high' you get from these foods. This is prescribed alongside lifestyle changes for obesity management.

Metabolic and bariatric surgery (MBS) is associated with a significantly lower risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type-2 diabetes and severe obesity.

For patients with type-2 diabetes and severe obesity, metabolic surgery appears to offer better protection against major heart events and death than treatment with GLP-1 medications alone. While surgery carries a small risk of complications, the long-term cardiovascular benefits outweigh these risks compared to pharmacological management. Patients should discuss these specific cardiovascular outcomes with their healthcare providers when choosing between surgical and medical management.

Gut microbiota composition and function are altered in type 2 diabetes, characterized by reduced diversity and decreased abundance of butyrate-producing bacteria, which is associated with insulin resistance and increased diabetes risk.

People with type 2 diabetes often have less diverse gut bacteria and fewer bacteria that produce butyrate. This is a consistent finding, but it doesn't mean there's a single 'bad bacteria' to target. Focus on dietary patterns that support overall microbial diversity.

If initial double combination therapy fails to control HbA1c, a triple combination of metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist is recommended as the best treatment to reduce cardiovascular events and mortality.

If your first two medications don't control your blood sugar, add a third: a combination of metformin, an SGLT-2 inhibitor, and a GLP-1 receptor agonist. This is the most effective way to protect your heart and kidneys based on current real-world evidence.

Insulin should be the first-line treatment if insulin deficiency is the predominant factor at the onset of type 2 diabetes, followed by cardio-renal protective medications.

If your body isn't making enough insulin, start with insulin therapy first. After stabilizing your blood sugar with insulin, add medications that protect your heart and kidneys (SGLT-2 inhibitors or GLP-1 receptor agonists).

Resmetirom, a selective thyroid hormone receptor beta (THRβ) agonist, significantly reduces hepatic steatosis, liver fibrosis, and serum lipid levels (LDL, TG, ApoB) in patients with MASLD, particularly those with fibrosis.

For patients with fatty liver disease who have developed early scarring (fibrosis), Resmetirom is a new medication that targets the liver specifically to burn fat and reduce scarring. It also lowers bad cholesterol (LDL) and triglycerides. Clinical trials show it significantly improves liver health markers.

Reducing insulin resistance, rather than strictly lowering blood glucose, is the primary mechanism for reducing cardiovascular risk in type 2 diabetes.

For patients with Type 2 Diabetes, focusing solely on lowering blood sugar may not be enough to protect your heart. The key to reducing cardiovascular risk is improving your body's sensitivity to insulin. This can be achieved through lifestyle changes (weight loss, diet, exercise), specific medications like Metformin or Pioglitazone, or newer drugs like GLP-1 agonists (e.g., Liraglutide) and SGLT2 inhibitors (e.g., Empagliflozin), which offer cardiovascular benefits beyond glucose control.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual/triple incretin agonists (e.g., tirzepatide, retatrutide) significantly reduce hepatic steatosis and liver enzymes in patients with MASLD, primarily through indirect mechanisms of weight loss and improved insulin resistance, though they may not consistently resolve fibrosis.

If you have MASLD, especially with diabetes or obesity, GLP-1 based therapies (like semaglutide or tirzepatide) are highly effective at reducing liver fat and inflammation. However, do not expect them to reverse advanced scarring (fibrosis) on their own. The benefit comes largely from the weight loss and metabolic control they provide, so they work best when combined with lifestyle changes.

Ketogenic diets produce superior short-term glycemic control (HbA1c reduction) compared to low-carbohydrate diets, but are not superior to other dietary patterns for long-term weight loss or metabolic outcomes.

If you have Type 2 Diabetes, a strict ketogenic diet (20-50g carbs/day) can lower your HbA1c faster than standard low-carb diets in the short term. However, do not expect it to help you lose more weight in the long run compared to other healthy diets. It is a tool for glycemic control, not a magic bullet for weight loss.

Chronic resistance exercise training increases skeletal muscle LAT1 protein content, but this increase is significantly blunted by concurrent leucine or whey protein supplementation compared to a placebo.

If you are doing resistance training, you will build muscle regardless of whether you take leucine or whey protein supplements. Interestingly, your body's expression of the LAT1 transporter (which moves leucine into cells) increased significantly more when you took a placebo compared to when you took leucine or whey. This suggests that supplementing with these specific compounds might blunt this specific molecular adaptation, even though it doesn't stop muscle growth. You don't need to avoid them, but don't expect them to maximize every single molecular marker.

Targeting specific inflammatory pathways (e.g., IL-1, TNFα, IL-6) with pharmacological antagonists can improve insulin sensitivity and glycemic control in patients with obesity and related inflammatory conditions.

In clinical settings, reducing inflammation through targeted medications can help manage blood sugar and insulin resistance in obese patients, especially those with co-existing inflammatory diseases. This supports the broader goal of reducing metabolic risk.

Tirzepatide improves cardiovascular risk factors, including lipid profiles and blood pressure, without increasing cardiovascular event risk in T2DM patients.

Beyond weight loss, Tirzepatide improves heart health markers by lowering bad fats (triglycerides, LDL) and raising good fats (HDL), while also lowering blood pressure. It does not appear to increase heart attack or stroke risk in T2DM patients.

Women with PCOS exhibit metabolic inflexibility (impaired substrate switching) comparable to women with Type 2 Diabetes, independent of BMI differences.

For women with PCOS, metabolic inflexibility is a core feature similar to Type 2 Diabetes, not just a side effect of being overweight. This means your body struggles to switch between burning fat and sugar efficiently. Focus on strategies that improve insulin sensitivity (like resistance training and managing carbohydrate timing) rather than just calorie restriction, as the underlying hormonal environment (androgens) drives this inflexibility.

Within PCOS populations, metabolic inflexibility is strongly associated with higher visceral adipose tissue and hyperandrogenemia (free testosterone/free androgen index).

If you have PCOS and struggle with metabolic flexibility, check your visceral fat and hormone levels. High free testosterone and abdominal fat are key drivers of this inflexibility. Addressing these specific markers may help improve your body's ability to switch fuel sources.

Adaptive thermogenesis is associated with significant hormonal changes, specifically decreased leptin and T3, and reduced resting heart rate.

Low leptin and T3 levels are expected during a cut and contribute to metabolic slowdown. This is a normal hormonal response to energy deficit.

GLP-1RAs reduce food intake and body weight by activating POMC neurons and inhibiting NPY/AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus.

GLP-1 medications also work in the brain's 'hunger center' (arcuate nucleus) by boosting 'stop eating' signals (POMC) and reducing 'start eating' signals (NPY/AgRP). This dual action helps reduce overall food intake and body weight.

Discontinuation of anti-obesity medications (AOMs) leads to significant weight regain starting at 8 weeks post-treatment, with the trajectory stabilizing by 26 weeks.

If you stop taking anti-obesity medication, expect to regain weight starting around 2 months later. This is a biological response to the loss of the drug's appetite-suppressing effects, not a lack of willpower. Long-term management likely requires ongoing treatment or intensive lifestyle support to counteract this regain.

GLP-1 analogs and SGLT-2 inhibitors are promising therapeutic modalities for the obese-diabetic phenotype of HFpEF, with GLP-1 analogs showing significant reduction in epicardial adipose tissue (EAT) and body weight.

Newer diabetes drugs (GLP-1s and SGLT-2 inhibitors) are highly effective for obese HFpEF patients. They help lose weight, reduce heart fat (EAT), and improve heart function. GLP-1s like semaglutide can lead to substantial weight loss (up to 10% or more).